Category: Pharmaceutical Industry
-
UPC CoA reverses invalidation of Amgen patent, clarifies standards for added matter and sufficient disclosure; infringement action to resume
In a high-stakes life sciences case, the UPC’s CoA has provided its most far-reaching clarifications on (in)validity to date.
-
Boehringer wins PI against Dr. Reddy’s that blocks generic empagliflozin (Jardiance) sales in UK pending October 2026 trial: patent thickets work
In some jurisdictions it pays off for Boehringer Ingelheim to have created a patent thicket around empaglifozin (Jardiance) involving use and formulation patents.
-
PI spate: Novo Nordisk just obtained 29 injunctions (26 over patent, 3 over UCL) against semaglutide rivals in Germany, served at CPHI fair
Context: What’s new: Novo Nordisk has just obtained, served and enforced a whopping 29 preliminary injunctions (PIs) against (mostly Asian and to a lesser extent European) companies offering the active pharmaceutical ingredient semaglutide and/or pharmaceuticals containing semaglutide at the CPHI fair. The pan-European law firm of Hoyng Rokh Monegier, in collaboration with UK firm Bristows,…
-
Munich I Regional Court’s written reasons for multi-country pharma PI: out-of-district defendants can be sued, German procedures apply
The Munich I Regional Court’s headnotes are highly instructive and make the court an attractive forum for cross-border injunctions.
-
Pharma patent litigation updates: Boehringer, Orion, Pfizer, Kaleo file fresh patent infringement suits in District of Delaware
The District of Delaware continues to receive a substantial volume of pharmaceutical patent infringement complaints, with an arthritis-related Pfizer suit and diabetes-related Boehringer suit among the latest.
-
AstraZeneca faces fresh mRNA patent infringement allegations in District of Delaware
Gene-editing tech company Factor Bioscience has sued AstraZeneca and its affiliate Cellectis over the infringement of three mRNA-related patents.
-
Federal Circuit partly grants Bayer second chance in defending rivaroxaban patent invalidation campaign
The Federal Circuit has partly affirmed and partly vacated a United States Patent and Trademark Office’s Patent Trial and Appeal Board decision that deemed one of Bayer’s rivaroxaban-related patents invalid, in a three-year case initiated by rivals Mylan Pharmaceuticals, Teva Pharmaceuticals, and Invagen Pharmaceuticals.
-
Moderna, Alnylam settle U.S. COVID vaccine patent infringement dispute
Alnylam has settled its three-year dispute against Moderna in the District of Delaware, after a precedential Federal Circuit decision found the patentee had acted as its own lexicographer in defining a key patent specification term, foreclosing its infringement allegations.
-
Doctrine of equivalents removes painkiller from German market: Grünenthal wins preliminary injunction on appeal
A pharma patent and unfair competition dispute has taken a remarkable turn as the Dusseldorf Higher Regional Court granted a preliminary injunction based on infringement by equivalents.
-
Regeneron makes strides in global Eylea patent enforcement campaign: settles with Sandoz, files fresh UK suits
Regeneron has settled its year-long patent infringement dispute with Sandoz over several patents related to its eye disease drug Eylea, and filed a fresh lawsuit against two more rivals over the same drug in the High Court of Justice for England & Wales.